Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Other HIV products by Year
Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) — U.S. sales ($M) ($M)
Gilead Sciences Other HIV products: $352M in FY2025, up 37.0% from a year earlier. That is the highest of the 10 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 352 | +37.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 257 | +8.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 238 | -17.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 290 | +113.2% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 136 | -59.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 332 | +1,006.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 30 | -25.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 40 | -7.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 43 | +4.9% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 41 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Other HIV products ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-other-us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.